Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naive UC (DAD-IO) Meeting Abstract

cited authors

  • McGregor, Bradley Alexander; Kwak, Lucia; Sonpavde, Guru P.; Berg, Stephanie A.; Choueiri, Toni K.; Bellmunt, Joaquim; Mantia, Charlene

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16